BIOVIE BIVI 深 沪
等待开盘 09-04 09:30:00 美东时间
1.67
+0.090
+5.70%
华盛通- 最 高1.69
- 今 开1.63
- 成交量 50.44万股
- 最 低 1.59
- 昨 收 1.58
- 总市值 1258.21万
- 52周最高 75.00
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.42
- 委 比 -92.23%
- 总股本 753.42万
- 历史最高 4609.80
- 量 比 1.83
- 振 幅 6.33%
- 历史最低 1.59
- 每 手 1
- 风险率 8.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
BioVie Inc. is currently enrolling patients for its Phase 2 ADDRESS-LC trial, focusing on Long COVID-related fatigue and cognitive impairment. The trial evaluates the efficacy of bezisterim, an anti-inflammatory agent, in a randomized, double-blind, placebo-controlled study. Over 400 million individuals globally have been affected by Long COVID, with no FDA-approved treatments available. The study, funded by the U.S. Department of Defense, aims t...
08-13 20:05
BioVie stock dips on pricing $12M securities offering
BioVie (NASDAQ:BIVI) has priced a public offering of 6 million units at $2.00 per unit, raising approximately $12 million in gross proceeds. Each unit includes one share of common stock and one warran...
08-08 14:56
BioVie Inc. Announces Pricing of $12 Million Public Offering
BioVie Inc. (NASDAQ: BIVI) announced the pricing of its underwritten public offering of 6 million units at $2.00 per unit, with each unit including one share of common stock and one warrant. The company expects gross proceeds of approximately $12 million before underwriting discounts and expenses. The warrants, exercisable at $2.50 per share, will expire in five years and commence trading on August 8, 2025. Proceeds will be used for working capit...
08-08 00:43
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
Bioventus Inc. has entered into a $400 million Senior Secured Credit Agreement, including a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement enhances liquidity, reduces the applicable interest margin by 75 basis points, and lowers annual term loan amortization from 10% to 5%. Proceeds were used to repay $333 million under the previous 2019 Credit Agreement, with $30 million from the new...
08-04 12:00
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
BioVie Inc. presented research on Bezisterim, a drug candidate modulating inflammation and insulin sensitivity, at the World Conference on Aging and Gerentology (WCAG-2025). The study showed that Bezisterim significantly decelerated biological aging in Alzheimer’s Disease patients, reducing age acceleration by up to 4.24 years on certain clocks. It also decreased inflammatory cytokines like TNFα, IL-6, and IL-17, and improved metabolic biomarkers...
07-24 12:00
BioVie Expands Board Amid Drug Development Momentum
The latest update is out from BioVie ( ($BIVI) ). On July 17, 2025, BioVie Inc....
07-24 05:27
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
BioVie Inc. has appointed Amy S. Chappell, MD, and Kameel D. Farag to its Board of Directors, bringing significant expertise in neuroscience drug development and financial growth. Dr. Chappell, a seasoned neurologist with extensive experience in CNS drug approvals, joins from Solaxa Inc. Mr. Farag, a financial leader with a track record in scaling biotech companies, previously led Aspen Neuroscience. Their expertise will support BioVie’s Phase 2 ...
07-22 12:00
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
BioVie Inc. presented findings at the World Aging and Rejuvenation Conference (ARC-2025) in Vienna, highlighting the potential of its drug candidate, bezisterim, in addressing aging and neurodegeneration through anti-inflammatory epigenetic mechanisms. Data from the Phase 3 NM101 study indicated that bezisterim may slow biological aging by 3.16 to 4.24 years, based on five epigenetic clocks, and improved metabolic and inflammatory biomarkers in p...
07-09 12:00
BioVie Announces 1-for-10 Reverse Stock Split
BioVie ( ($BIVI) ) has issued an update. On June 23, 2025, BioVie Inc.’s stockh...
06-28 05:50
